Recently, an anti-transcriptional intermediary factor 1 gamma (TIF1γ) antibody was reported as a marker for predicting cancer association in patients with DM, since TIF1γ, which regulates the tumor growth factor pathway, has been reported to be associated with tumor growth in some malignancies [5]. Here, TRIM33 is linked to diabetes mellitus.